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with migraine headache prophylaxis with topiramate versus
amitriptyline. METHODS: Lifetime incidence and costs of car-
diovascular disease (CVD) were estimated for patients receiving
topiramate or amitriptyline as migraine headache prophylaxis.
Projections were based on a model of the clinical and economic
consequences of overweight and obesity, and data from a recent
six-month controlled clinical trial of these agents, which demon-
strated that they were equally effective in preventing migraines.
Analyses were undertaken for a hypothetical cohort of 1000
women, aged 35 to 44 years at therapy initiation, with pre-treat-
ment body mass index (BMI) of 28. Topiramate patients were
assumed to experience a 1.26 unit decrease in BMI at six months,
based on clinical trial data; and amitriptyline patients were
assumed to experience an increase of 1.51; changes were
assumed to persist over a lifetime. Model outcomes included
expected lifetime cumulative incidence of coronary heart disease
(CHD) and stroke, and life expectancy. Expected lifetime costs
were calculated based on estimated event risk and associated
medical-care costs, using a third-party payer perspective. Costs
were discounted at 3% annually. RESULTS: As a result of
changes in BMI, the estimated prevalence of hypertension, hyper-
cholesterolemia, and diabetes was higher for amitriptyline versus
topiramate at all future ages. Amitriptyline patients were 
also estimated to develop an additional 18 cases of CHD (per
1000 patients) compared to those receiving topiramate. Life
expectancy was 0.4 years longer for topiramate patients, and
their lifetime cumulative direct costs of CVD and metabolic
disease were about $3500 lower than those for amitriptyline.
CONCLUSION: Migraine headache prophylaxis with topira-
mate rather than amitriptyline may yield important clinical and
economic beneﬁts as a result of differences in induced changes
in body weight.
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OBJECTIVES: We investigate the impact of recurrent relapses
on short- and long-term health care costs in the United States.
Relapses in multiple sclerosis (MS) are a major burden on
patients’ welfare and related health care costs, and have been
shown to impact residual disability. While relapse costs have
been reported previously, no publication has examined the
impact of recurrent relapses on total health care costs.
METHODS: We used medical (International Classiﬁcation of
Diseases-9 diagnoses) and pharmacy claims from a large, US
National Health Plan database to identify MS patients with >=1
relapse who had enrolled in the plan between 2002–2004, and
who had continuous enrolment 6 months pre- and 12 months
post-index relapse. Costs were estimated based on claim charges,
and were adjusted to project the amount in 2005 US dollars.
Analyses were stratiﬁed by newly or previously diagnosed
patients, and the number of relapses. Costs are presented in 90-
day intervals in reference to the index relapse period (days 0–30).
RESULTS: Newly diagnosed patients with >=2 relapses had
higher monthly costs compared with patients with 1 relapse only
at days 0–30 (index relapse) ($26,890 vs. $16,121), 31–90
($3597 vs. $1506), and 271–360 ($3768 vs. $1074). Although
previously diagnosed patients with >=2 relapses had costs similar
to those of patients with 1 relapse only at index relapse at days
0–30 ($21,350 vs. $21,015), monthly costs were higher for
patients with >=2 relapses at days 31–90 ($3792 vs. $2712) and
remained higher at days 271–360 ($3636 vs. $1676). Monthly
costs were generally higher for previously diagnosed patients
with the exception of the acute phase of relapse (days 0–30) in
the >=2 relapses subset. CONCLUSION: Recurrent relapses are
associated with increased costs, both in the acute phase of man-
aging a relapse and during the follow-up year in both newly diag-
nosed and previously diagnosed patients.
PND13
HEALTH CARE COSTS AND UTILIZATION FOR ALZHEIMER’S
DISEASE PATIENTS
Zhao Y1, Kuo TC2,Weir S3, Kramer MS2,Ash AS4
1Eli Lilly and Company, Indianapolis, IN, USA, 2DxCG, Inc, Boston, MA,
USA, 3University of Massachusetts Medical School, Shrewsbury, MA,
USA, 4Boston University, Bosotn, MA, USA
OBJECTIVES: To examine comorbidity associated with
Alzheimer’s disease (AD) and cost drivers using administrative
claims. METHODS: We studied over-age-65 individuals with
pharmacy beneﬁts with employer-sponsored Medicare supple-
mental insurance in 2003–2004. AD patients were identiﬁed by
having ≥1 claim with an AD diagnosis or ≥1 ﬁlled prescription
for medication used exclusively for AD treatment in 2003. We
used propensity scoring to select demographically-matched, 
non-demented Controls (3 : 1 ratio to AD) and compared these
groups for disease prevalence (via a comprehensive classiﬁcation
system, Diagnostic Cost Groups (DCGs)), 2004 cost distribu-
tions, and reasons for ER visits and inpatient admissions. We
used logistic regression to assess the marginal contribution of AD
to the most common reasons for ER and inpatient admissions,
using DCGs to control for total illness burden. RESULTS: Com-
pared with controls (n = 75,327), AD patients (n = 25,109) have
more comorbid medical conditions (8.1 vs. 6.5) and higher
($13,936 vs. $10,369) but less variable (CVs = 181 vs. 324)
costs. Both groups expend one-third of overall costs on inpatient
services, ≤29% on prescriptions, and ≥38% on outpatient ser-
vices. Not only do more AD patients use ERs (27% vs. 42%)
and hospitals (30% vs. 20%), but their hospitalizations are
longer (3.38 vs. 1.93 days). Chest pain and contusion/superﬁcial
injury are the top two reasons for ER visits for both groups.
Three of the top 4 reasons for inpatient admissions are also the
same: pneumonia, hip fracture and heart failure. However, even
after controlling for their excess illness burden, AD patients are
at higher risk for hospitalizations due to hip fracture and pneu-
monia (odds ratios = 2.29 and 1.48, respectively). CONCLU-
SION: AD patients have signiﬁcantly more comorbid disease,
and are more likely to incur ER visits and inpatient admissions,
than age-and-sex matched controls, even after adjusting for
comorbidity differences.
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OBJECTIVES: Pharmaceutical options for insomnia that treat
both sleep induction and maintenance have only recently been
launched in the U.S. The economic impact of treatment patterns
with older drugs has not been thoroughly investigated in the lit-
erature. We hypothesized that since the older drugs only pro-
vided beneﬁt for sleep induction, insomniacs who alternate
therapy within one year of initiation would have greater eco-
nomic burden compared to maintainers. METHODS: Treated
insomnia patients were identiﬁed from Medstat Marketscan
claims database with at least one prescription for existing insom-
nia agents during the study period (05/01/01 to 11/30/03).
